The novel coronavirus infection COVID-19 and lung diseases: a pneumologist’s view

Česká verzia

Authors: František Sándor
Authors place of work: Klinika pneumológie a ftizeológie LF UK a UNB, Nemocnica Ružinov
Published in the journal: Forum Diab 2022; 11(1): 10-14
Category:

Summary

According to the WHO statistics COPD (Chronic Obstructive Pulmonary Disease) is the third leading cause of mortality worldwide. During more than 2 years of world pandemic caused by the novel coronavirus COVID-19 (COronaVIrus Disease 2019), multiple studies have seen light elucidating the correlation between chronic lung diseases such as COPD, bronchial asthma, lung cancer, ILD (Interstitital Lung Diseases) and the clinical course of COVID-19 infection. The common staple manifestation is the development of various degrees of hypoxemic respiratory failure frequently requiring hospital stay. Most clinical studies are consistent in their conclusions, that these patients have not just an increased risk of severe disease, yet also suffer from higher mortality due to COVID-19 infection. There is also some evidence supporting adequate control of chronic lung diseases minimizes the long-term consequences of novel coronavirus infection. In the light of these data, apart from aggressive vaccination campaign, it is paramount in this group of patients to ensure early diagnosis followed by prompt treatment modalities in order to minimize mortality and long term complications of acute COVID-19 infection.

Keywords:

hypoxemic respiratory failure – COVID-19 disease – chronic pulmonary diseases

Zdroje

1. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19. Implications for the Cardiovascular System. Circulation 2020; 142(1): 68–78. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047549>.
2. Informace dostupné z WWW: <https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(COPD)>.
3. Singh D, Agusti A, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J 2019; 53(5): 1900164. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.00164–2019>.
4. Coutard B, Valle C, de Lamballerie X et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020; 176: 104742. Dostupné z DOI: <http://dx.doi.org/10.1016/j.antiviral.2020.104742>.
5. Shang J, Ye G, Shi K et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020; 581(7807): 221–224. Dostupné z DOI: <http://dx.doi.org/10.1038/s41586–020–2179-y>.
6. Mallia P, Message SD, Gielen V et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011; 183(6): 734–742. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.201006–0833OC>.
7. Gerayelia FV, Milnea S, Cheung C et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. Eclinical Medicine 2021; 33:100789. Dostupné z DOI: <http://dx.doi.org/10.1016/j.eclinm.2021.100789>.
8. Informace dostupné z WWW: <https://www.thelancet.com/journals/eclinm/article/PIIS2589–5370(21)00069–9/fulltext>.
9. Sitek AN, Ade JM, Chiarella SE et al. Outcomes among patients with COVID-19 and asthma: A systematic review and meta-analysis. Allergy Asthma Proc 2021; 42(4): 267–273. Dostupné z DOI: <http://dx.doi.org/10.2500/aap.2021.42.210041>.
10. Aggarwal AN, Agarwal R, Sahajal D et al. Impact of Asthma on Severity and Outcomes in COVID-19. Respir Care 2021; 66(12): 1912–1923. Dostupné z DOI: <http://dx.doi.org/10.4187/respcare.09113>.
11. Ho KS, Howell D, Rogers L et al. The relationship between asthma, eosinophilia, and outcomes in coronavirus disease 2019 infection. Ann Allergy Asthma Immunol 2021; 127(1): 42–48. Dostupné z DOI: <http://dx.doi.org710.1016/j.anai.2021.02.021>.
12. Cottin V, Hirani NA, Hotchkin DL et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Review; 27(150): 180076. Dostupné z DOI: <http://dx.doi.org/10.1183/16000617.0076–2018>.
13. 13.Lee H, Choi H, Yang B et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021; 58(6): 2004125. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.04125–2020>.
14. Esposito AJ, Menon AA, Ghosh AJ et al. Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study. Am J Respir Crit Care Med 2020; 202(12): 1710–1713. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.202006–2441LE>.
15. Drake TM, Docherty AB, Harrison EM et al. ISARIC4C Investigators. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med 2020; 202(12): 1656–1665. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.202007–2794OC>.
16. Peravali M, Joshi I, Ahn J et al. A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients with Lung Cancer with Coronavirus Disease 2019. JTO Clin Res Rep 2021; 2(3): 100141. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jtocrr.2020.100141>.
17. Peravali M, Joshi I, Ahn J et al. A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019. JTO Clin Res Rep 2021; 2(3): 100141.Dostupné z DOI: <http://dx.doi.org/10.1016/j.jtocrr.2020.100141>.
18. GuilhermeNader M, Colombo Bonadio R, Encinas Sejas ON et al. Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19. JCO Glob Oncol 2021; 7: 1084–1092. Dostupné z DOI: <http://dx.doi.org/10.1200/GO.21.00087>.
19. Stokes EK, Zambrano LD, Anderson KN et al. Coronavirus Disease 2019 Case Surveillance – United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69(24): 759. Dostupné z DOI: <http://dx.doi.org/10.15585/mmwr.mm6924e2>.
20. Cohen PA, Hall LE, John JN et al. The Early Natural History of SARS-CoV-2 Infection: Clinical Observations from an Urban, Ambulatory COVID-19 Clinic. Mayo Clin Proc 2020; 95(6): 1124–1126. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2020.04.010>.
21. Young S, Fernandez PM. Skin manifestations of COVID-19. Cleveland Clin J Med 2020. Dostupné z DOI: <https://doi.org/10.3949/ccjm.87a.ccc031>.
22. Ramakrishnan S, Nicolau DV, jr, Langford B et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; 9(7): 763–772. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–2600(21)00160–0>.
23. Weinreich DM, Sivapalasingam S, Norton T et al. Outtcomes in Outpatients with Covid-19 D.M. N Engl J Med 2021; 385: e81. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2108163>.
24. Dougan M, Nirula A, Azizad M et al. [BLAZE-1 Investigators]. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med 2021; 385(15): 1382–1392. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2102685>.
25. Informace dostupné z WWW: <https://www.gsk.com/en-gb/ media/press-releases/sotrovimab-retains-activity>.
26. Informace dostupné z WWW: <https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate>.
27. Bernal AJ, Gomes da Silva MM, Musungaie DB et al. Molnupiravir for Oral Treat-ment of Covid-19 in Nonhospitalized Patients MOVe-OUT Study Group. N Engl J Med 2022; 386(6): 509–520. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2116044>.
28. Ospina-Tascón GA, Calderón-Tapia LE, García AF et al. Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients with Severe COVID-19: A Randomized Clinical Trial. JAMA 2021; 326(21): 2161– 2171. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2021.20714>.
29. Carter C, Aedy H, Notter J. COVID-19 disease: Non-Invasive Ventilation and high frequency nasal oxygenation. Clinics in Integrated Care 2020; 1:100006. Dostupné z DOI: <http://dx.doi.org/10.1016/ j.intcar.2020.100006>.
30. Bertaina M, Nuñez-Gil IJ, Franchin L et al. [HOPE COVID-19 investigators]. Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry. Emerg Med J 2021; 38(5): 359–365. Dostupné z DOI: <http://dx.doi.org/10.1136/emermed-2020–210411>.
31. Horby P, Lim WS, Emberson JR et al. [RECOVERY Collaborative Group]. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384(8): 693–704. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2021436>.
32. [RECOVERY Collaborative Group]. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397(10285): 1637–1645. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(21)00676–0>.33. FDA News Release: Coronavirus (COVID-19) Update: FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-
19. Dostupné z WWW: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19>.
34. Marconi VC, Ramanan AV, de Bono S et al. [COV-BARRIER Study Group]. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebocontrolled phase 3 trial. Lancet Respir Med 2021; 9(12): 1407–1418. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–2600(21)00331–3>.
35. Kalil AC, Patterson TF, Mehta AK et al. [ACTT-2 Study Group Members]. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 2021; 384(9): 795–807. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2031994>.
36. Myall KJ, Mukherjee B, Castanheira AM et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann Am Thorac Soc 2021; 18(5): 799–806. Dostupné z DOI: <http://dx.doi.org/10.1513/AnnalsATS.202008–1002OC>.
37. Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J 2021; 58(6): 2101956. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.01956–2021>.
38. Marvisi M, Ferrozzi F, Balzarini L et al. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution. Int J Infect Dis 2020; 99: 485–488. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijid.2020.08.054>.
39. Myall KJ, Mukherjee B, Castanheira AM et al. Persistent post-COVID-19 interstitial lung disease. an observational study of corticosteroid treatment. Ann Am Thorac Soc 2021; 18(5): 799–806. Dostupné z DOI: <http://dx.doi.org/10.1513/AnnalsATS.202008–1002OC>.
40. Sonnweber T, Sahanic S, Pizzini A et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J 2021; 57(4): 2003481. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.03481>.